Established 1999
123jump.com - U.S. Financial Information Archive: 90,000 Annual and 10-K reports – 20,000 Global news stories - 3,500 IPO reports - 1,700 - Earnings Calls – 320 Fund Interviews – 10-year Annual earnings on 4,500 stocks – 20 Quarterly earnings on 3,600 stocks – 1,800 IPO prospectuses – 1,200 Economic data releases
     
   
 
  Quotes Find Symbol:
 Company Links
+1-250-7442488
http://www.aspreva.com/
 Management    Source: Company documents
 Earnings Calls
Earnings Release Dates : 31st October 2007 , 1st August 2007 , 1st August 2007 , 13th June 2007
Audio
 Annual Reports
 Quarterly Earnings - ASPV
Sequential Earnings Growth | Quarterly Earnings by Year | Quarterly Earnings Growth by Year

Source: Company filings    Q1:March  Q2:June  Q3:September  Q4:December
 Annual Earnings- ASPV
Annual earnings growth

Diluted EPS Excluding Extraordinary Items     Source: Company filings
 123JUMP News:
Aspreva's shares rose 34.5% on the first day of trading   
Things were very light for IPOs last week   
Things were very light for IPOs last week   
 IPO Reports:
Aspreva Pharmaceuticals Corp.
CellCept is an orally delivered immunosuppressant agent. An immunosuppressant agent is a medication that slows or halts immune system activity. CellCept converts to its active form, mycophenolic acid, in the body. Mycophenolic acid prevents transplant rejection by preventing the proliferation and activation of T- and B-cells. T- and B-cell survival and proliferation depends on the ability of the cells to produce guanine nucleotides, one of the basic structural units of DNA.
More...




   
© 1999-2008 123jump.com. All rights reserved   
 

Warning: Unknown: Your script possibly relies on a session side-effect which existed until PHP 4.2.3. Please be advised that the session extension does not consider global variables as a source of data, unless register_globals is enabled. You can disable this functionality and this warning by setting session.bug_compat_42 or session.bug_compat_warn to off, respectively. in Unknown on line 0